Key Highlights
- 18 percent was the one-day gain for Verastem (NASDAQ:VSTM) on Wednesday, October 14, 2026, after it reported early data for VS-7375, an oral KRAS G12D inhibitor. The company announced a USD 250 million stock offering and a CEO transition plan the same day.
- 4 of 8 second-line pancreatic cancer patients responded to VS-7375 at 900 mg daily, a 50 percent rate, while the broader second-line or later group of 22 evaluable patients showed 41 percent, including two complete responses. These are small cohorts from a Phase 1/2 study.
- 43 percent was the confirmed response rate in 23 lung cancer patients at 600 mg daily, measured at 4.4 months, with a 72 percent six-month progression-free rate. Verastem (NASDAQ:VSTM) says over 200 patients with KRAS G12D tumors were treated in the full study.
- 26 percent of KRAS mutations are G12D, the most common variant in human cancers, according to the company release. FDA review documents suggested a more modest G12D benefit for Rasonque, the approved drug from Revolution Medicines (NASDAQ:RVMD), which Verastem is now challenging.
What Verastem Reported
Verastem released data on October 14, 2026 from a Phase 1/2 trial of VS-7375, an oral drug that binds both the active and inactive states of the KRAS G12D protein. In metastatic pancreatic cancer, 22 evaluable patients received 900 mg daily. The six-month progression-free rate was 67 percent, the overall survival rate was 80 percent, and 16 patients were still on treatment at six months. Chief executive Dan Paterson said the company had set a new benchmark in pancreatic cancer. That is a management view, and safety data were not in the material reviewed.
The Rasonque Comparison
Revolution Medicines won FDA approval for Rasonque (daraxonrasib) in August 2026 for previously treated pancreatic cancer. Reported confirmed response rates were 36 percent in the second line and 21 percent in the third line or later. FDA review documents released in early October suggested a more modest benefit in G12D tumors, and Revolution fell 6 percent on October 8, 2026. Leerink Partners analyst Andrew Berens called it a crack in the armor. A direct comparison is unsafe: cohorts are small and populations differ.
Offering, Dilution and Risks
The USD 250 million offering funds the next stage. Selling new shares raises cash but spreads ownership across a bigger count, so each existing share claims a smaller slice of any future profit. Pricing terms and the cash balance were not confirmed in the material reviewed. Phase 3 in first-line pancreatic cancer is targeted by the end of 2026, with colorectal and lung trials in the first half of 2027. Paterson said partnering is likely.
Where Things Stand
It depends. A 50 percent second-line response is eye-catching, but it comes from 8 patients, and Verastem (NASDAQ:VSTM) has to repeat it in a Phase 3 trial that is not yet running. The 18 percent gain on October 14, 2026 already prices some success, while the USD 250 million offering added a supply of shares. Revolution Medicines (NASDAQ:RVMD) now faces questions on G12D. The next catalysts are the Phase 3 start targeted by year-end, offering terms in the filing, and any partnership. Early response rates often shrink in larger studies.






Please wait processing your request...